glp 1 weight loss clinic lansing ny Medical GLP-1 Weight Loss Special |

References Srensen TIA, Martinez AR, Jrgensen TSH

Much of the recent analyst discussion links this updated target range to retatrutide Phase 3 data, with bulls highlighting GLP-1 leadership and bears questioning how much future obesity growth is already embedded

Important limitation: Neither is FDA-approved, and human clinical data relies heavily on animal models and observational reports

Beyond glycemic control, GLP-1 receptor agonists slow gastric emptying, prolonging the sensation of fullness after meals

This underscores the importance of not assuming all symptoms will self-resolve, particularly if they are severe or persistent